The Advances in Cardiometabolic Research eBook brings together expert perspectives on the evolving landscape of obesity, diabetes, metabolic dysfunction, and related cardiovascular and renal diseases. Sponsored by hVIVO, this collection explores how advances in early-phase clinical research, biomarker science, and trial design are helping accelerate the development of next-generation cardiometabolic therapies.
As the field moves beyond traditional measures such as body weight and BMI, researchers are adopting more sophisticated approaches that prioritize metabolic health, body composition, and clinically meaningful outcomes.
This eBook examines the growing impact of GLP-1 therapies, the changing expectations for obesity trials, and the increasing importance of precision biomarkers, integrated laboratory strategies, and patient-centered study designs. It also highlights best practices for planning cardiometabolic clinical trials, optimizing early-phase diabetes and MASLD studies, addressing renal and hepatic challenges in drug development, and improving outcomes in diabetic kidney disease.
Featuring scientific articles and expert insights from Professor Thomas Forst, Chief Medical Officer at hVIVO, this resource provides practical guidance for researchers, clinical developers, and pharmaceutical professionals seeking to navigate the complexities of modern cardiometabolic research. Whether designing innovative clinical trials or advancing novel therapies, readers will gain valuable perspectives on the strategies shaping the future of cardiometabolic medicine.
About hVIVO plc
hVIVO plc is a science‑led early‑phase drug development company purpose‑built to meet the growing complexity of modern clinical research. The Company operates an integrated early‑phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‑ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.
With industry‑leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‑growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‑built human challenge units in the world, complemented by additional early‑phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.
The company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‑of‑concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.
.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.